Biovie (BIVI) Return on Capital Employed (2017 - 2026)
Biovie (BIVI) posted Return on Capital Employed of 112.45% for Q1 2026, down 33.82% sequentially from 84.03% in Q4 2025, and down 2764.0% YoY from 4.22% in Q1 2025.
Biovie (BIVI) Return on Capital Employed (2017 - 2026) Analysis & Trends
Biovie has reported Return on Capital Employed for 10 years, with the latest figure at 112.45% in Q1 2026.
- Quarterly Return on Capital Employed fell 2764.0% year-over-year to 112.45% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 112.45% (down 2764.0% YoY) and the FY2025 annual result came in at 85.58%, up 6910.0% from the prior year.
- Return on Capital Employed eased to 112.45% in Q1 2026 per BIVI's latest filing, from 84.03% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 84.03% in Q4 2025 and troughed at 605.19% in Q1 2022.
- A 5-year average of 196.15% and a median of 143.77% in 2023 frame the typical range for Return on Capital Employed.
- The widest YoY moves for Return on Capital Employed: up 148568 bps in 2022, down 54536 bps in 2022.
- Over 5 years, Return on Capital Employed stood at 129.9% in 2022, then sank by 296 bps to 513.76% in 2023, then soared by 79 bps to 108.76% in 2024, then climbed by 23 bps to 84.03% in 2025, then slumped by 34 bps to 112.45% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 112.45%, 84.03%, and 85.28% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Biovie | 14.17 Mn | 14.17 Mn | - | -187.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -187.41% |
| Mar 31, 2026 | -112.45% |
| Dec 31, 2025 | -84.03% |
| Sep 30, 2025 | -85.28% |
| Jun 30, 2025 | -86.70% |
| Mar 31, 2025 | -84.81% |
| Dec 31, 2024 | -108.76% |
| Sep 30, 2024 | -155.18% |
| Jun 30, 2024 | -168.14% |
| Mar 31, 2024 | -271.12% |
| Dec 31, 2023 | -513.76% |
| Sep 30, 2023 | -290.51% |
| Jun 30, 2023 | -175.76% |
| Mar 31, 2023 | -143.77% |
| Dec 31, 2022 | -129.90% |
| Sep 30, 2022 | -175.61% |
| Jun 30, 2022 | -143.57% |
| Mar 31, 2022 | -605.19% |
| Dec 31, 2021 | -650.57% |
| Sep 30, 2021 | -1,123.04% |